Anoop TM, Basu PK, Chandramohan K, Thomas A, Manoj S. Evolving utility of exosomes in pancreatic cancer management. World J Methodol 2023; 13(3): 46-58 [PMID: 37456979 DOI: 10.5662/wjm.v13.i3.46]
Corresponding Author of This Article
Thattungal Manoharan Anoop, MBBS, MD, DM, DNB, FRCP Edin, Associate Professor, Department of Medical Oncology, Regional Cancer Center, Medical College Campus, Kumarapuram Road, Thiruvananthapuram 695011, Kerala, India. dranooptm@yahoo.co.in
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Methodol. Jun 20, 2023; 13(3): 46-58 Published online Jun 20, 2023. doi: 10.5662/wjm.v13.i3.46
Evolving utility of exosomes in pancreatic cancer management
Thattungal Manoharan Anoop, Palash Kumar Basu, K Chandramohan, Ajai Thomas, S Manoj
Thattungal Manoharan Anoop, Ajai Thomas, S Manoj, Department of Medical Oncology, Regional Cancer Center, Medical College Campus, Thiruvananthapuram 695011, Kerala, India
Palash Kumar Basu, Department of Avionics, Indian Institute of Space Science & Technology (IIST), Thiruvananthapuram 695547, Kerala, India
K Chandramohan, Surgical Oncology, Regional Cancer Center, Thiruvananthapuram 695011, Kerala, India
Author contributions: Anoop TM designed the study, drafted the manuscript; Basu PK participated in the design and draft of the manuscript; Chandramohan K participated in the design and draft of the manuscript; Thomas A participated in the design and draft of the manuscript; Manoj S participated in the design and draft of the manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Thattungal Manoharan Anoop, MBBS, MD, DM, DNB, FRCP Edin, Associate Professor, Department of Medical Oncology, Regional Cancer Center, Medical College Campus, Kumarapuram Road, Thiruvananthapuram 695011, Kerala, India. dranooptm@yahoo.co.in
Received: March 22, 2023 Peer-review started: March 22, 2023 First decision: April 17, 2023 Revised: May 2, 2023 Accepted: May 31, 2023 Article in press: May 31, 2023 Published online: June 20, 2023 Processing time: 89 Days and 19.3 Hours
Abstract
Despite the development of newer oncological treatment, the survival of patients with pancreatic cancer (PC) remains poor. Recent studies have identified exosomes as essential mediators of intercellular communications and play a vital role in tumor initiation, metastasis and chemoresistance. Thus, the utility of liquid biopsies using exosomes in PC management can be used for early detection, diagnosis, monitoring as well as drug delivery vehicles for cancer therapy. This review summarizes the function, and clinical applications of exosomes in cancers as minimally invasive liquid biomarker in diagnostic, prognostic and therapeutic roles.
Core Tip: The determination and identification of biomarkers using liquid biopsy can enable the early detection, monitoring, therapeutic interventions, risk of relapse, therapeutic targets and identification of resistance mechanisms in pancreatic cancer (PC). There has been a recent interest in use of exosomes as biomarker in PC management. Exosomes loaded with multiple diagnostic molecules can be isolated from different body fluids and can be used for making the exosome markers-based liquid biopsy more attractive for initial tumor detection, monitoring, and prognostic assessment of PC.
